Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Modulate Chemoradiotherapy Response in Cervical Cancer Spheroids
- PMID: 40732337
- PMCID: PMC12299787
- DOI: 10.3390/ph18071050
Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Modulate Chemoradiotherapy Response in Cervical Cancer Spheroids
Abstract
Background: Bone marrow mesenchymal stem cells (BM-MSCs) are significant in chemo- and radiotherapy resistance. Previous research has focused on BM-MSCs, demonstrating their functional involvement in cancer progression as mediators in the tumor microenvironment. They play multiple roles in tumorigenesis, angiogenesis, and metastasis. BM-MSC-derived exosomes (BM-MSCs-exo) are small vesicles, typically 50-300 nm in diameter, isolated from BM-MSCs. Some studies have demonstrated the tumor-suppressive effects of BM-MSCs-exo. Objective: This study aimed to investigate their role in modulating the impact of chemoradiotherapy (CRT) in different types of cervical cancer spheroid cells. Methods: The spheroids after treatment were subject to size measurement, cell viability, and caspase activity. Then, the molecular mechanism was elucidated by Western blot analysis. Results: We observed a reduction in spheroid size and an increase in cell death in HeLa spheroids, while no significant changes in size or cell viability were found in SiHa spheroids. At the molecular level, CRT treatment combined with BM-MSCs-exo in HeLa spheroids induced apoptosis through the activation of the NF-κB pathway, specifically via the NF-κB1 (P50) transcription factor, leading to the upregulation of apoptosis-related molecules. In contrast, CRT combined with BM-MSCs-exo in SiHa spheroids exhibited an opposing effect: although cellular viability decreased, caspase activity also decreased, which correlated with increased HSP27 expression and the subsequent downregulation of apoptotic molecules. Conclusion: Our study provides deeper insight into the potential of BM-MSCs-exo in cervical cancer treatment, supporting the development of more effective and safer therapeutic strategies for clinical application.
Keywords: bone marrow mesenchymal stem cells (BM-MSCs); cancer therapy; cervical cancer; chemo- and radiotherapy resistance; exosomes.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures







Similar articles
-
Endothelial cell-derived extracellular vesicles modulate the therapeutic efficacy of mesenchymal stem cells through IDH2/TET pathway in ARDS.Cell Commun Signal. 2024 May 27;22(1):293. doi: 10.1186/s12964-024-01672-0. Cell Commun Signal. 2024. PMID: 38802896 Free PMC article.
-
Comparative Analysis of microRNA Expression Profiles of Exosome-Mimetic Vesicles, Exosomes, and Originating Human Bone Marrow Mesenchymal Stem Cells.Stem Cells Dev. 2025 Jul;34(13-14):304-316. doi: 10.1089/scd.2025.0005. Epub 2025 Jun 17. Stem Cells Dev. 2025. PMID: 40526399
-
Mesenchymal stem cells promote ovarian reconstruction in mice.Stem Cell Res Ther. 2024 Apr 23;15(1):115. doi: 10.1186/s13287-024-03718-z. Stem Cell Res Ther. 2024. PMID: 38650029 Free PMC article.
-
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.Cochrane Database Syst Rev. 2015 Apr 7;(4):CD010260. doi: 10.1002/14651858.CD010260.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2022 Aug 22;8:CD010260. doi: 10.1002/14651858.CD010260.pub3. PMID: 25847525 Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous